Navigation Links
Stemline Therapeutics' Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
Date:11/8/2012

ine Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients. In a multicenter Phase 1/2 trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. In Phase 1/2 trials, Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs) in adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma, as well as an OS benefit in adult patients with refractory or recurrent glioblastoma compared with historical data. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:

Mark Jacobson
Director, Corporate Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
Sixth Floor
New York, NY 10022
Tel: 646-502-2307
Email: mjacobson@stemline.com
www.steml
'/>"/>

SOURCE Stemline Therapeutics, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... commands the vital signs monitoring devices market with ... . The North American and European vital signs ... $907.0 million, respectively, by the end of 2013. They ... rising number of elderly people across these economies. The ... demand owing to the rising demand for home health ...
(Date:9/2/2014)... Reportlinker.com announces that a new market ... Acute Heart Failure Global Clinical Trials Review, ... Acute Heart Failure Global Clinical Trials ... clinical trial report, "Acute Heart Failure Global Clinical ... Acute Heart Failure clinical trial scenario. This report ...
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... 2007 - CELSION CORPORATION,(AMEX:CLN) today announced the ... using ThermoDox(R), to treat non-resectable liver,cancer. The ... Research,and Development Agreement (CRADA) was performed at ... Institutes of Health, under,the leadership of Dr. ...
... NEW YORK--(BUSINESS WIRE)--May 30, 2007 - INNOVIVE ... data from a Phase I,trial of INNO-406, ... for Gleevec(R)-resistant or,treatment-intolerant chronic myelogenous leukemia, will ... Clinical Oncology Annual,Meeting. The meeting takes place ...
Cached Medicine Technology:Celsion Completes Enrollment in Phase I Liver Cancer Study 2Celsion Completes Enrollment in Phase I Liver Cancer Study 3Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... soccer tickets. The first week in September will be ... Teams from Brazil, Colombia, Mexico, Chile, Ecuador and Bolivia ... The following matches will take place between September 5th - ... Stadium on Tuesday, September 9th , Mexico vs. ...
(Date:9/2/2014)... NY (PRWEB) September 02, 2014 The ... VisitandCare.com , was designed to help doctors manage foreign ... to boost patient conversion rates and clink revenue. Since ... 60 percent increase in sales revenue and a 70 ... CRM software in their own healthcare practices. , With ...
(Date:9/2/2014)... you are hospitalized, but your outpatient doctor does ... office for follow-up care, but your doctor does ... stay? Missing or incomplete communication from hospitals ... to poor experiences and lead to hospital readmissions. ... implementing guidelines can improve hospitals, communication during patient ...
(Date:9/2/2014)... Experimental Biology and Medicine that appears ... and medicine of microphysiological systems" and describes the ... Program directed by the National Center for Advancing ... Health (NIH) and funded in part by the ... Agency (DARPA) and the Food and Drug Administration ...
(Date:9/2/2014)... Ohio (PRWEB) September 02, 2014 For ... managed IT security and network services company, has been ... nation. Inc. magazine's Inc. 5000 list highlights America's fastest ... each year since the list inception in 2007. , ... has grown 144 percent over the past three years. ...
Breaking Medicine News(10 mins):Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 3Health News:CentraComm Named to Inc. 5000 for 8th Consecutive Year 2
... battle super bugs, including MRSA, has found its way to ... as Tygacil, is one of the few new antibiotics to ... ,Micro organisms have undergone mutations that enabled them ... infections, such as MRSA, in hospitals. ,The new ...
... new study suggests that male circumcision could significantly reduce ... findings that has been published in the Journal PLoS ... that suggested circumcision reduced HIV infection risk in heterosexual ... researchers have used that data and conducted the research, ...
... study in the July issue of Archives of General Psychiatry, ... fact more prone to depression. //The study on more than ... percent increased risk of developing mood and anxiety disorders including, ... is an important public health issue because both of these ...
... agreed to reconduct lab tests to find out whether a ... as early as 2003, after eight of its scientists alleged ... Ministry of Health said it was conducting new lab tests ... ,"In accordance with World Health Organisation and China's diagnostic standards ...
... compares two common inhalers for patients suffering from ... reduces respiratory-related hospitalizations and respiratory deaths, but the ... of cases -- increases respiratory deaths. ... 22 trials with 15,276 participants found that common ...
... Researchers at the Institute Of Cancer Research have discovered a ... the disease.// ,It is found that if a ... being diagnosed with breast cancer doubles. This would serve as ... risk of cancer and thereby help treat and prevent the ...
Cached Medicine News:Health News:New Drugs To Combat Mutant Bugs 2Health News:Practise Of Male Circumcision In Africa May Reduce HIV Risks 2Health News:COPD Patients Using Beta-agonist Inhalers Are at Risk 2
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
... FDA approved, Avagard antiseptic hand prep ... hand scrub brushes and antimicrobial soaps. ... hands for surgery, it's fast-acting and ... for up to six hours without ...
... antimicrobial skin cleanser will not leave your ... frequent washings. With persistent Antimicrobial action, CHG ... microorganisms, including gram-negative and gram-positive bacteria, fungi, ... a 15 second hand wash. The solution ...
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Medicine Products: